Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity

US6512000B1 · kind B1 · utility

Assignee

• BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

• Ralf Anderskewitz · Laupheim, DE
• Christine Braun · Giubiasco, CH
• Hans Briem · Bremen, DE
• Bernd Disse · Ingelheim am Rhein, DE
• Christoph Hoenke · Ingelheim am Rhein, DE
• Hans Michael Jennewein · Wiesbaden, DE
• Georg Speck · Ingelheim am Rhein, DE

Key dates

• Filing date: Aug 8, 2000
• Grant date: Jan 28, 2003
• Expiry date: Aug 8, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for treating diseases in which tryptase inhibitors may be of thereapeutic value, which comprises the administration of a thereapeutic amount of a compound of the formula The invention also comprises novel compounds of the formula (I). Exemplary is 2-[2-(4-amidinophenyl)ethyl]-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(pyridin-3-yl-methyl)-N-methyl-amide-hydrochloride.